Damian Wild

List of Publications by Year
in descending order

76 papers	4,439 citations	136885 32 h-index	102432 66 g-index
79 all docs	79 docs citations	79 times ranked	3285 citing authors

#	Article	IF	Citations
1	Quantitative myocardial perfusion 82Rb-PET assessed by hybrid PET/coronary-CT: Normal values and diagnostic performance. Journal of Nuclear Cardiology, 2022, 29, 464-473.	1.4	10
2	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	1.2	12
3	Molecular Imaging in neuroendocrine neoplasias. Presse Medicale, 2022, 51, 104115.	0.8	2
4	Radiolabeled Somatostatin Analogsâ€”A Continuously Evolving Class of Radiopharmaceuticals. Cancers, 2022, 14, 1172.	1.7	27
5	Molecular Imaging of Neuroendocrine Neoplasms. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2662-e2670.	1.8	9
6	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 2022, 14, 3317.	1.7	2
7	Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 581-594.	2.6	29
8	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	1.3	120
9	Investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI. PLoS ONE, 2021, 16, e0253078.	1.1	2
10	Accuracy comparison of various quantitative [99mTc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses. EJNMMI Research, 2021, 11, 60.	1.1	4
11	Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?. Journal of Nuclear Medicine, 2021, 62, 44S-50S.	2.8	8
12	Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 727-739.	1.4	5
13	Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4903-e4916.	1.8	15
14	Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: A clinical pharmacoscintigraphy study. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 22-30.	2.0	8
15	New Directions in Imaging Neuroendocrine Neoplasms. Current Oncology Reports, 2021, 23, 143.	1.8	5
16	Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. Cancers, 2021, 13, 6290.	1.7	4
17	Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 836-847.	0.4	3
18	Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. Journal of Nuclear Medicine, 2020, 61, 520-526.	2.8	53

#	Article	IF	Citations
19	Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. Journal of Nuclear Cardiology, 2020, 27, 1456-1463.	1.4	44
20	Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clinical Nuclear Medicine, 2020, 45, e386-e392.	0.7	13
21	Brunnerâ€™s Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging. Case Reports in Endocrinology, 2020, 2020, 1-4.	0.2	2
22	Comparison of [18F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity. EJNMMI Research, 2020, 10, 85.	1.1	10
23	Innovative imaging of insulinoma: the end of sampling? A review. Endocrine-Related Cancer, 2020, 27, R79-R92.	1.6	44
24	Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.. Journal of Clinical Oncology, 2020, 38, e16700-e16700.	0.8	0
25	Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. Case Reports in Oncology, 2020, 13, 1373-1380.	0.3	0
26	Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?. Journal of Nuclear Medicine, 2019, 60, 393-399.	2.8	42
27	68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5843-5852.	1.8	36
28	Prevalence and determinants of exerciseâ€induced left ventricular dysfunction in patients with coronary artery disease. European Journal of Clinical Investigation, 2019, 49, e13112.	1.7	0
29	In Vivo Biokinetics of ¹⁷⁷Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry. Contrast Media and Molecular Imaging, 2019, 2019, 1-7.	0.4	11
30	Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT. Clinical Nuclear Medicine, 2019, 44, e347-e348.	0.7	7
31	Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients. Journal of Nuclear Medicine, 2019, 60, 812-816.	2.8	21
32	Molecular imaging for neuroendocrine tumours. Swiss Medical Weekly, 2019, 149, w20017.	0.8	5
33	Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality. Clinical Research in Cardiology, 2018, 107, 824-835.	1.5	4
34	Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. Journal of Nuclear Medicine, 2018, 59, 547-548.	2.8	6
35	Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease. Clinical Chemistry, 2018, 64, 386-395.	1.5	30
36	Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine, 2018, 59, 909-914.	2.8	65

#	Article	IF	Citations
37	Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. Journal of Nuclear Medicine, 2018, 59, 915-921.	2.8	121
38	Combining high-sensitivity cardiac troponin and B-type natriuretic peptide in the detection of inducible myocardial ischemia. Clinical Biochemistry, 2018, 52, 33-40.	0.8	13
39	Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2318-2327.	3.3	82
40	Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease. Clinical Chemistry, 2018, 64, 1596-1606.	1.5	19
41	Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study). Swiss Medical Weekly, 2018, 148, w14682.	0.8	12
42	Diagnostic and Prognostic Value of Lead aVR During Exercise Testing in Patients Suspected of Having Myocardial Ischemia. American Journal of Cardiology, 2017, 119, 959-966.	0.7	8
43	Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷Lu-DOTATATE: The Mass Effect. Journal of Nuclear Medicine, 2017, 58, 1435-1441.	2.8	100
44	Diagnostic value of ST-segment deviations during cardiac exercise stress testing: Systematic comparison of different ECG leads and time-points. International Journal of Cardiology, 2017, 238, 166-172.	0.8	7
45	PET/CT Imaging of Unstable Carotid Plaque with ⁶⁸Ga-Labeled Somatostatin Receptor Ligand. Journal of Nuclear Medicine, 2017, 58, 774-780.	2.8	27
46	Somatostatin Receptor Antagonists for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 61S-66S.	2.8	188
47	The Spatial Relationship between Apparent Diffusion Coefficient and Standardized Uptake Value of 18F-Fluorodeoxyglucose Has a Crucial Influence on the Numeric Correlation of Both Parameters in PET/MRI of Lung Tumors. Contrast Media and Molecular Imaging, 2017, 2017, 1-11.	0.4	0
48	Gastroenteropancreatic neuroendocrine tumours (GEP-NET) â€“ Imaging and staging. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 45-57.	2.2	90
49	Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia. American Heart Journal, 2016, 173, 8-17.	1.2	55
50	Direct comparison of cardiac troponin I and cardiac troponin T in the detection of exercise-induced myocardial ischemia. Clinical Biochemistry, 2016, 49, 421-432.	0.8	21
51	Delayed release of brain natriuretic peptide to identify myocardial ischaemia. European Journal of Clinical Investigation, 2015, 45, 1175-1183.	1.7	9
52	Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases. Patient Safety in Surgery, 2015, 9, 23.	1.1	9
53	Non-invasive nuclear myocardial perfusion imaging improves the diagnostic yield of invasive coronary angiography. European Heart Journal Cardiovascular Imaging, 2015, 16, 842-847.	0.5	20
54	Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of Nuclear Medicine, 2015, 56, 1075-1078.	2.8	104

#	Article	IF	Citations
55	Incremental Value of a Single High-sensitivity Cardiac Troponin I Measurement to Rule Out Myocardial Ischemia. American Journal of Medicine, 2015, 128, 638-646.	0.6	31
56	Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT. Endocrine, 2015, 50, 821-823.	1.1	34
57	Role of molecular imaging in the detection of neuroendocrine tumour. Cancer Imaging, 2014, 14, .	1.2	0
58	Prognostic Value of â€œRoutineâ€•Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 615-621.	1.1	25
59	Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of Nuclear Medicine, 2014, 55, 1248-1252.	2.8	197
60	B-type Natriuretic Peptide and Clinical Judgment in the Detection of Exercise-induced Myocardial Ischemia. American Journal of Medicine, 2014, 127, 427-435.	0.6	18
61	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes and Endocrinology,the, 2013, 1, 115-122.	5.5	153
62	Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2013, 54, 364-372.	2.8	184
63	Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Frontiers in Endocrinology, 2012, 3, 158.	1.5	47
64	Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN) Tj ETQq0 0 0 rgBT /Overlock 1	0.4	114
65	First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible. Journal of Nuclear Medicine, 2011, 52, 1412-1417.	2.8	157
66	Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas. Journal of Nuclear Medicine, 2011, 52, 1073-1078.	2.8	141
67	GLP-1â€"Receptor Scanning for Imaging of Human Beta Cells Transplanted in Muscle. New England Journal of Medicine, 2010, 363, 1289-1290.	13.9	112
68	Exendin-4â€"Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT. Journal of Nuclear Medicine, 2010, 51, 1059-1067.	2.8	141
69	Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4398-4405.	1.8	238
70	Glucagon-like Peptide 1â€"Receptor Scans to Localize Occult Insulinomas. New England Journal of Medicine, 2008, 359, 766-768.	13.9	181
71	Use of B-type natriuretic peptide in the detection of myocardial ischemia. American Heart Journal, 2006, 151, 1223-1230.	1.2	79
72	Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16436-16441.	3.3	425

#	Article	IF	Citations
73	[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of Nuclear Medicine, 2006, 47, 2025-33.	2.8	123
74	68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 724-724.	3.3	167
75	Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. American Journal of Medicine, 2005, 118, 1287.e9-1287.e16.	0.6	55
76	DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1338-1347.	3.3	274